# Inozyme Pharma Inc. (INZY)

Source: https://www.quantisnow.com/company/INZY
Generated: 2026-11-20T06:47:37.115Z

- Ticker: INZY
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2020
- Website: inozyme.com

## About

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

## Latest INZY news and filings

- 2025-07-17 23:54 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-inozyme-pharma-inc-6124527)
- 2025-07-11 10:02 UTC [SEC Form 15-12G filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-inozyme-pharma-inc-6117418)
- 2025-07-03 23:16 UTC [SEC Form 4] [SVP, CFO & Head of BD Subramanian Sanjay closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/svp-cfo-head-of-bd-subramanian-sanjay-closing-all-direct-6111768)
- 2025-07-03 23:08 UTC [SEC Form 4] [COO Winton Matthew closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/coo-winton-matthew-closing-all-direct-ownership-in-the-company-6111767)
- 2025-07-03 23:07 UTC [SEC Form 4] [Director Bolte Axel closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-bolte-axel-closing-all-direct-ownership-in-the-company-6111766)
- 2025-07-03 23:04 UTC [SEC Form 4] [SEC Form 4 filed by Director Sullivan Lynne Marie](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-sullivan-lynne-marie-6111761)
- 2025-07-03 23:03 UTC [SEC Form 4] [CEO & Chairman Treco Douglas A closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/ceo-chairman-treco-douglas-a-closing-all-direct-ownership-in-6111758)
- 2025-07-03 22:59 UTC [SEC Form 4] [SEC Form 4 filed by Director Hopfner Robert Lorne](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hopfner-robert-lorne-6111750)
- 2025-07-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-inozyme-pharma-inc-6106964)
- 2025-07-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-inozyme-pharma-inc-6106949)
- 2025-07-01 13:54 UTC [SEC Form 25-NSE filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-inozyme-pharma-inc-6105268)
- 2025-07-01 13:51 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-inozyme-pharma-inc-6105265)
- 2025-07-01 13:49 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-inozyme-pharma-inc-6105264)
- 2025-07-01 13:48 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-inozyme-pharma-inc-6105261)
- 2025-07-01 13:45 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-inozyme-pharma-inc-6105258)
- 2025-07-01 13:44 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-inozyme-pharma-inc-6105254)
- 2025-07-01 13:43 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-inozyme-pharma-inc-6105252)
- 2025-07-01 13:29 UTC [SEC Form POS AM filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-inozyme-pharma-inc-6105226)
- 2025-07-01 13:27 UTC [SEC Form POS AM filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-inozyme-pharma-inc-6105223)
- 2025-07-01 13:25 UTC [SEC Form 8-K] [Inozyme Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update](https://www.quantisnow.com/insight/inozyme-pharma-inc-filed-sec-form-8-k-notice-of-delisting-6105218)
- 2025-07-01 13:21 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-inozyme-pharma-inc-6105204)
- 2025-07-01 13:18 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-inozyme-pharma-inc-6105199)
- 2025-07-01 12:45 UTC [Mergers & Acquisitions] [BioMarin Announces Completion of Acquisition of Inozyme](https://www.quantisnow.com/insight/biomarin-announces-completion-of-acquisition-of-inozyme-6105065)
- 2025-06-27 20:05 UTC [SEC Form 4] [COO Winton Matthew was granted 14,355 shares, increasing direct ownership by 194% to 21,743 units (SEC Form 4)](https://www.quantisnow.com/insight/coo-winton-matthew-was-granted-14355-shares-increasing-direct-ownership-6101770)
- 2025-06-27 20:05 UTC [SEC Form 4] [CEO & Chairman Treco Douglas A was granted 2,815 shares, increasing direct ownership by 7% to 43,861 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-chairman-treco-douglas-a-was-granted-2815-shares-increasing-6101763)
- 2025-06-27 20:05 UTC [SEC Form 4] [SVP, CFO & Head of BD Subramanian Sanjay was granted 6,813 shares, increasing direct ownership by 21% to 39,701 units (SEC Form 4)](https://www.quantisnow.com/insight/svp-cfo-head-of-bd-subramanian-sanjay-was-granted-6813-6101760)
- 2025-06-20 23:31 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-inozyme-pharma-inc-6094648)
- 2025-06-20 23:29 UTC [SEC Form 8-K] [SEC Form 8-K filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-inozyme-pharma-inc-6094639)
- 2025-06-20 21:00 UTC [Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders](https://www.quantisnow.com/insight/inozyme-pharma-inc-announces-postponement-of-2025-annual-meeting-of-6094222)
- 2025-06-17 11:28 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-inozyme-pharma-inc-6089146)
- 2025-06-17 10:15 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-inozyme-pharma-inc-6089046)
- 2025-06-13 20:56 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-inozyme-pharma-inc-6086387)
- 2025-06-04 21:09 UTC [SEC Form SCHEDULE 13G filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-inozyme-pharma-inc-6072894)
- 2025-06-04 20:51 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-inozyme-pharma-inc-6072750)
- 2025-06-04 20:32 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-inozyme-pharma-inc-6072602)
- 2025-06-02 11:35 UTC [SEC Form 8-K] [SEC Form 8-K filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-inozyme-pharma-inc-6066492)
- 2025-06-02 11:14 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9 filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-sc-14d9-filed-by-inozyme-pharma-inc-6066458)
- 2025-06-02 10:25 UTC [SEC Schedule TOT] [SEC Form SC TO-T filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-sc-to-t-filed-by-inozyme-pharma-inc-6066351)
- 2025-05-20 20:00 UTC [SEC Form 4] [Director Bolte Axel exercised 157,230 shares at a strike of $0.98, increasing direct ownership by 59% to 423,926 units (SEC Form 4)](https://www.quantisnow.com/insight/director-bolte-axel-exercised-157230-shares-at-a-strike-of-6050012)
- 2025-05-20 01:23 UTC [SEC Form SC14D9C filed by Inozyme Pharma Inc.](https://www.quantisnow.com/insight/sec-form-sc14d9c-filed-by-inozyme-pharma-inc-6049218)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/INZY
- Earnings history: https://www.quantisnow.com/earnings/INZY
- Dividend history: https://www.quantisnow.com/dividends/INZY
- Insider transactions: https://www.quantisnow.com/insiders/INZY
- Options chain: https://www.quantisnow.com/options/INZY
- SEC 8-K filings only: https://www.quantisnow.com/company/INZY/8-k
- RSS and alerts for INZY: https://www.quantisnow.com/docs/rss-feeds.md
